News & Updates

Maternal NAFLD ups risk of adverse pregnancy outcomes

09 Jan 2025

Pregnant women with nonalcoholic fatty liver disease (NAFLD) face a greater risk of adverse pregnancy events, suggests a genome-wide association study.

Maternal NAFLD ups risk of adverse pregnancy outcomes

09 Jan 2025

Oral bacteria a risk factor for HNSCC development

09 Jan 2025 by

A prospective nested case-control study yields compelling evidence that oral bacteria are a risk factor for the development of head and neck squamous cell carcinoma (HNSCC), which comprises cancers of the oral cavity, pharynx, and larynx.

Oral bacteria a risk factor for HNSCC development

09 Jan 2025

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

07 Jan 2025 by

The first interim analysis of the phase III LEAP-012 study shows the potential of lenvatinib, pembrolizumab, and transarterial chemoembolization (TACE) as a new treatment option for intermediate-stage hepatocellular carcinoma (HCC).

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

07 Jan 2025

Original New Drug Application Approvals by US FDA (16-31 December 2024)

07 Jan 2025

New drug applications approved by US FDA as of 16-31 December 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 December 2024)

07 Jan 2025

Vedolizumab after resection helps prevent CD recurrence

05 Jan 2025

For patients with Crohn’s disease (CD) who are scheduled to undergo ileocolonic resection, initiating vedolizumab treatment promptly after the procedure has the potential to prevent recurrence, according to the results of the REPREVIO study.

Vedolizumab after resection helps prevent CD recurrence

05 Jan 2025

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024 by

Adding pembrolizumab to trastuzumab and chemotherapy significantly improves overall survival (OS) in patients with advanced unresectable or metastatic HER2+ gastric/gastroesophageal junction (G/GEJ) adenocarcinoma and in those with PD-L1 CPS ≥1, according to the protocol-specified final OS analysis of the KEYNOTE-811 trial presented at ESMO Asia 2024.

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

27 Dec 2024

New UC guideline endorses early use of advanced therapies

27 Dec 2024 by

The American Gastroenterological Association (AGA), in an update to its living practice guideline, recommends the early use of advanced therapies for the pharmacological management of moderate-to-severe ulcerative colitis (UC) in adult outpatients.

New UC guideline endorses early use of advanced therapies

27 Dec 2024

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

27 Dec 2024 by

The evidence supporting an upfront daratumumab-containing regimen as the SoC for AL amyloidosis is reaffirmed by the significant OS benefit demonstrated in the final analysis of ANDROMEDA

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

27 Dec 2024

PPI use raises risk of intestinal Behçet disease

24 Dec 2024

Treatment with proton pump inhibitors (PPIs) may contribute to a higher incidence of intestinal Behçet Disease (BD) in patients with BD, suggest the results of a study.

PPI use raises risk of intestinal Behçet disease

24 Dec 2024

Newer hepatitis B vaccine provides superior protection for people with HIV

23 Dec 2024 by

People living with HIV who have no history of hepatitis B virus (HBV) infection or documented response to vaccination appear to have a stronger immune response to the hepatitis B vaccine with a cytosine phosphoguanine adjuvant (HepB-CpG) than that with an aluminum hydroxide adjuvant (HepB-alum).

Newer hepatitis B vaccine provides superior protection for people with HIV

23 Dec 2024

News & Updates

Filter by Specialty:

Specialty:

Maternal NAFLD ups risk of adverse pregnancy outcomes

Maternal NAFLD ups risk of adverse pregnancy outcomes

Oral bacteria a risk factor for HNSCC development

Oral bacteria a risk factor for HNSCC development

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

Lenvatinib-pembrolizumab plus TACE promising for intermediate-stage liver cancer

Original New Drug Application Approvals by US FDA (16-31 December 2024)

Original New Drug Application Approvals by US FDA (16-31 December 2024)

Vedolizumab after resection helps prevent CD recurrence

Vedolizumab after resection helps prevent CD recurrence

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

KEYNOTE-811: Add-on pembrolizumab improves OS in HER2+ gastroesophageal cancer

New UC guideline endorses early use of advanced therapies

New UC guideline endorses early use of advanced therapies

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

Hitting OS endpoint reaffirms frontline daratumumab-VCd as SoC for AL amyloidosis

PPI use raises risk of intestinal Behçet disease

PPI use raises risk of intestinal Behçet disease

Newer hepatitis B vaccine provides superior protection for people with HIV

Newer hepatitis B vaccine provides superior protection for people with HIV